ZEDRA
11.2.2020 09:02:09 CET | Business Wire | Press release
Fast growing and acquisitive ZEDRA has announced its latest acquisition, this time in Poland. ZEDRA will acquire Awans Corporate Services, one of Poland’s oldest corporate services specialists, which has been offering accounting and administration services to local companies, corporations and individuals, for over 20 years. This new acquisition follows on from deals in Singapore, the Isle of Man, Switzerland, Nordic markets signed and announced in 2019.
With a focus on local entrepreneurs and medium sized companies, Awans Corporate Services is a leading provider of accounting, human resources and payroll management services to companies based in Poland. The company also offers traditional corporate services, including incorporation services, cash management and business advisory.
Unveiling the acquisition, Ivo Hemelraad, CEO of ZEDRA said: “This latest deal will mark our first move into the vibrant and fast growing Central European markets. With a population of nearly 38 million, together with a strong tradition for business startups and growth, we see Poland as a dynamic and important new market for ZEDRA. I am looking forward to welcoming the staff and clients of Awans Corporate Services to ZEDRA.” Piotr Augustyniak, founder of Awans Corporate Services, who is to become ZEDRA’s Head of Central Europe at completion, stated: “As one of Poland’s oldest providers of high quality corporate services solutions, we will be bringing a unique depth of knowledge and expertise to ZEDRA.”
Bartek Bielski, Managing Director of Awans Corporate Services, which will be renamed ZEDRA Poland following completion, added: “Our nearly 20 staff have always focussed on providing best in class solutions to our clients. The opportunity to become part of ZEDRA, with its proactive and positive ‘do more, achieve more’ approach, and getting access to its international network of professionals is one which we found compelling and certainly in the best interest of our staff and clients”.
The deal will bring ZEDRA’s existing headcount to over 550 industry experts and expand its global footprint to 14 countries, spanning Asia, Oceania, the Americas and Europe.
Editor notes
About ZEDRA
https://www.zedra.com/boilerplate/
About Awans Corporate Services
Awans Corporate Services is one of the companies with the longest history on the Polish market providing financial services and business support in the area of accounting and administration services.
The team consists of experienced specialists in the field of corporate services. Awans Corporate Services provides reliable and comprehensive accounting, human resources and payroll management services, as well as cost-effective solutions in the design and administration of companies and business consulting for small and medium-sized companies, corporations and individuals, in particular in the liberal professions (freelancers), ensuring ongoing compliance with Polish law and tax regulations.
Awans Corporate Services gained trust of many foreign companies, supporting them in developing business projects in Poland.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005134/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom